# Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia

> **NCT02662569** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 986 (actual)

## Conditions studied

- Diabetes, Hyperlipidemia, Mixed Dyslipidemia

## Interventions

- **BIOLOGICAL:** Evolocumab
- **DRUG:** Atorvastatin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02662569
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-14
- **Primary completion:** 2017-12-06
- **Final completion:** 2017-12-06
- **Target enrollment:** 986 (ACTUAL)
- **Last updated:** 2019-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02662569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02662569, "Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02662569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*